Integra Looks Ahead To Adhesion Barrier Application For DuraGen Matrix

Integra LifeSciences intends to begin a U.S. multi-site clinical trial in the second half of this year to evaluate DuraGen Plus matrix as a barrier to adhesion following spinal and cranial surgery